BCX-3607

• Description :

  BCX-3607 is an orally active tissue factor/factor VIIa (TF-FVIIa) inhibitor (IC50: 4 nM) . BCX-3607 blocks the extrinsic coagulation pathway by inhibiting the TF-FVIIa complex and significantly prolongs the prothrombin time (PT) . BCX-3607 has a higher selectivity for TF-FVIIa than other serine proteases (such as thrombin, FXa, etc.) . BCX-3607 can reduce thrombus weight and inflammatory response, and has both anti-thrombotic and anti-inflammatory effects. BCX-3607 can be used in the study of thrombosis-related diseases[1].

• CAS Number :

  [885684-79-7]

• UNSPSC :

  12352005

• Target :

  Others

• Related Pathways :

  Others

• Field of Research :

  Cardiovascular Disease

• Smiles :

  O=C(C1=CC(C(NCC(C)C)=O)=CC=C1C2=CC=C(C=C)C=C2CNC3=NC=C(C(N)=N)C=C3)O

• Molecular Formula :

  C27H29N5O3

• Molecular Weight :

  471.55

• References & Citations :

  [1]Kotian PL, et al. Design, synthesis, and structure-activity relationships of selective biphenyl antithrombotic tissue factor/factor VIIa inhibitors. Eur J Med Chem. 2025 May 6;294:117708.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported